Who
Liisa Ann Bayko
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Kalaris Therapeutics.
In numbers
- Trades disclosed
- 2
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 20 Jul 2026
- Last trade
- 20 Jul 2026
- Last filed
- 20 Jul 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Jul 2026filed 20 Jul 2026 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —220,000 at $0.00 | filing |
| 20 Jul 2026filed 20 Jul 2026 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —220,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.